Risk and Management of Patients with Cancer and Heart Disease

Cardiol Ther. 2023 Jun;12(2):227-241. doi: 10.1007/s40119-023-00305-w. Epub 2023 Feb 9.


Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient's myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients' functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

Keywords: Anthracycline; Cardiotoxicity; Heart failure; Risk stratification.

Publication types

  • Review